D-0095-2023 Class II Ongoing

Recalled by Eugia US LLC — East Windsor, NJ

FDA drug recall D-0095-2023 was initiated by Eugia US LLC on Dec 28, 2022 and is designated Class II. Reason for recall: Presence of Particulate Matter: Customer complaint of dark particles found inside the vial The recall status is ongoing. Affected quantity: 45,250 vials.

Recall details

Product Type
Drugs
Report Date
Jan 11, 2023
Initiation Date
Dec 28, 2022
Voluntary/Mandated
Voluntary: Firm initiated
Product Quantity
45,250 vials

Product description

Acyclovir Sodium Injection 1,000 mg per 20 mL* (50 mg/mL); Single Dose 20mL Vial, Rx only, Distributed by: AuroMedics Pharma LLC, 279 Princeton-Hightstown Rd, E. Windsor, NJ 08520; Made in India. NDC 55150-155-20

Reason for recall

Presence of Particulate Matter: Customer complaint of dark particles found inside the vial

Distribution pattern

Nationwide in the USA

Code information

Lot # AC22004, Expiry: 08/2023

Source

Dataset
openFDA drug recall enforcement reports
FDA record
This recall in openFDA (JSON)
Enforcement Report
Search FDA's Enforcement Report for D-0095-2023
openFDA file date
Nov 10, 2026
Loaded by RegDataLab
Nov 11, 2026

These dates say when openFDA published the data file and when RegDataLab last loaded it.

Source: openFDA record for D-0095-2023. Report a data issue: hello@regdatalab.com.